postoperative cognitive decline
Conditions
Interventions
The pharmacy will randomize patients to receive placebo (normal saline
placebo group) or ketanest (S(+)-ketamine
Eurocept BV, Ankeveen, NL) according to the LUMC protocol. This protocol states:
1. Initiate administration prior to surgical incision
2. Start with an intravenous bolus administration of 0.35 mg/kg
Sponsors
Leiden University Medical Center
Eligibility
Inclusion criteria
Inclusion criteria: Patients planned for elective surgery lasting > 2 1 h that require postoperative pain relief will be enrolled in the study after written informed consent is obtained.
Exclusion criteria
Exclusion criteria: Exclusion criteria: • age 35 kg/m2, • history or present psychiatric disease, • untreated/uncontrolled hypertension (with a diastolic blood pressure > 100 mmHg) • epilepsy, • increased intracranial pressure, • untreated hypertension, • untreated ischemic cardiac disease, • inability to communicate in the Dutch language, • inability to give informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| • To assess the effect of perioperative ketamine on postoperative cognitive function on day 1 and 30 following surgery. | — |
Secondary
| Measure | Time frame |
|---|---|
| • To assess the effect of perioperative ketamine on postoperative pain and perioperative analgesics consumption on days 1 and 2 following surgery and persistent pain as measured on day 30 following surgery. • To assess the effect of perioperative ketamine on depth of anesthesia and sedation (postoperatively) and nociceptive level during anesthesia. • To assess side effects during ketamine administration: hypertension, tachycardia, nausea/vomiting, psychomimetic side effects, lightheadedness/dizziness, drug high and elevated liver enzymes. • The assess the effect of ketamine on inflammatory marker C-reactive protein on day 1 after surgery. | — |
Contacts
Public ContactM. Velzen, van
LUMC, Anesthesiology, P5 Albinusdreef 2
Outcome results
None listed